DayOneBio_Logo_RGB_Square_large.jpg
Day One to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
November 18, 2021 08:00 ET | Day One Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing...
DayOneBio_Logo_RGB_Square_large.jpg
Day One Reports Third Quarter 2021 Financial Results and Corporate Progress
November 08, 2021 16:50 ET | Day One Biopharmaceuticals, Inc.
Enrollment Progresses in the Pivotal Phase 2 FIREFLY-1 Clinical Trial of DAY101 in Patients with pLGG; Initial Data Expected in 1H 2022 Upcoming CTOS Meeting to Highlight Single Agent Activity of...
DayOneBio_Logo_RGB_Square_large.jpg
Day One Announces Presentation at 2021 Connective Tissue Oncology Society (CTOS) Virtual Annual Meeting
November 03, 2021 08:00 ET | Day One Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing...
DayOneBio_Logo_RGB_Square_large.jpg
Day One Appoints Jaa Roberson as Chief People Officer
September 13, 2021 07:00 ET | Day One Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing...
DayOneBio_Logo_RGB_Square_large.jpg
Day One Appoints Scott Garland to Board of Directors
August 17, 2021 07:00 ET | Day One Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing...
DayOneBio_Logo_RGB_Square_large.jpg
Day One Reports Second Quarter 2021 Financial Results and Corporate Progress
August 10, 2021 16:05 ET | Day One Biopharmaceuticals, Inc.
DAY101 Granted Rare Pediatric Disease Designation from FDA DAY101 Granted Orphan Designation from European Commission Dosed the First Patients in Pivotal FIREFLY-1 Clinical Trial of DAY101 in...
DayOneBio_Logo_RGB_Square_large.jpg
Day One Biopharmaceuticals to Participate at the 2021 Wedbush PacGrow Healthcare Virtual Conference
August 04, 2021 08:00 ET | Day One Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing...
DayOneBio_Logo_RGB_Square_large.jpg
Day One Receives FDA Rare Pediatric Disease Designation for DAY101 for the Treatment of Pediatric Low-Grade Glioma
July 27, 2021 07:00 ET | Day One Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing...
DayOneBio_Logo_RGB_Square_large.jpg
Day One Receives Orphan Designation from the European Commission for DAY101 for the Treatment of Glioma
June 21, 2021 07:00 ET | Day One Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies...
DayOneBio_Logo_RGB_Square_large.jpg
Day One Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
June 01, 2021 16:01 ET | Day One Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., June 01, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing...